A Phase 1 interventional study of RO7126209 and Placebo in Alzheimers Disease, sponsored by Hoffmann-La Roche. Completed at 1 site in United States. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-09.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Alzheimer Disease by Hoffmann-La Roche — 3 open to participants now, 8 under way, 4 of them phase 3. Alzheimer Disease · Hoffmann-La Roche.
Among the 40 studies in Alzheimer Disease by Hoffmann-La Roche, this one is the 34th largest by enrollment, is one of 3 that started in 2019, is one of 13 in phase 1, and was the 26th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →3 of the 40 studies in Alzheimer Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 7 more countries
Ages 55–80
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 12 more countries
Ages 50–90
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 18 Years to 40 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 13 · Phase 3 14
First in 2006; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 247 across the 40 interventional studies. Of the 32 that completed or were terminated, 18 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
3 of the studies in Alzheimer Disease by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06402838Hoffmann-La RocheA Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | 2026-11-19 |
| NCT07234942Hoffmann-La RocheA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) | 2027-03-31 |
| NCT04639050Hoffmann-La RocheBrainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Alzheimer Disease by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study BP41192 is a randomized, adaptive, placebo-controlled parallel group study to investigate the safety, tolerability, immunogenicity and pharmacokinetics of single-ascending intravenous (IV) doses of RO7126209 in healthy participants. RO7126209 is being developed for the treatment of Alzheimer's Disease.
This study uses a parallel group design, with participants recruited in 5 planned sequential cohorts. Additional cohort(s) may be added if dose escalation stopping criteria are not met after cohort 5. Participants will receive a single IV dose of either RO7126209 or placebo. RO7126209 doses will be administered in ascending order. After the starting dose, subsequent doses will be selected in an adaptive manner during study conduct based on emerging safety, tolerability and PK data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Cohorts 1-5, there were ten participants in total who received placebo, two in each cohort.
Drug: Placebo
Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.1 mg/kg).
Drug: RO7126209
Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.4 mg/kg).
Drug: RO7126209
Healthy volunteers will be administered a single intravenous dose of RO7126209 (1.2 mg/kg).
Drug: RO7126209
Healthy volunteers will be administered a single intravenous dose of RO7126209 (3.6 mg/kg).
Drug: RO7126209
Healthy volunteers will be administered a single intravenous dose of RO7126209 (7.2 mg/kg).
Drug: RO7126209
Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.
Participants will be administered a single intravenous dose of matching placebo.
Percentage of Participants With Adverse Events (AEs)
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.
Time frame: Up to approximately 9 weeks
Concentration at the End of Infusion (Cend) of RO7126209
Plasma concentrations of RO7126209 were measured by a specific and validated assay at specified timepoints. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
Time frame: Day 1
Area Under the Plasma Concentration Versus Time Curve From Zero to 24 h Postdose (AUC0-24h) of RO7126209
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
Time frame: Days 1 and 2
Area Under the Plasma Concentration Versus Time Curve From Zero to 168h Postdose (AUC0-168h) of RO7126209
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
Time frame: Days 1, 2, 3, 4, 5 and 8
Area Under the Plasma Concentration Versus Time Curve From Zero to the Last Measurable Concentration (AUC0-last) of RO7126209
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
Time frame: Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf)
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
Time frame: Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57
Terminal Rate Constant (Lambda z) of RO7126209
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
Time frame: Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57
Apparent Terminal Half-Life (T1/2) of RO7126209
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
Time frame: Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57
Total Body Clearance Calculated as Dose/AUC (CL) of RO7126209
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
Time frame: Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57
Volume of Distribution at Steady-State (Vss) of RO7126209
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
Time frame: Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57
Cerebrospinal Fluid (CSF) Concentration of RO7126209
RO7126209 CSF concentrations were measured by a specific and validated method. Geometric Mean and Coefficient of Variation data are presented below.
Time frame: Day 3 and Day 5
Percentage of Participants With Anti-RO7126209 Antibodies (ADAs)
The numbers and proportions of Anti-Drug Antibody (ADA) positive participants and ADA negative participants at baseline (baseline prevalence) and after study drug administration (post-baseline incidence during both the treatment and follow-up periods) were summarized per dose group during both the treatment and follow-up period.
Time frame: Days 1, 8, 29 and 57
The study was conducted at 1 center in 1 country.
| Milestone | Placebo | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|---|
| Started | 10 | 4 | 4 | 6 | 6 | 6 |
| Completed | 10 | 3 | 2 | 5 | 6 | 6 |
| Not completed | 0 | 1 | 2 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 |
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.
| Percentage of Participants | Placebo | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 80.0 | 75.0 | 50.0 | 83.3 | 100.0 | 100.0 |
Plasma concentrations of RO7126209 were measured by a specific and validated assay at specified timepoints. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
| µg/mL | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|
| Concentration at the End of Infusion (Cend) of RO7126209 | 1.80 ± 15.9 | 7.93 ± 21.3 | 22.2 ± 17.6 | 85.7 ± 22.9 | 160 ± 26.5 |
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
| hr.µg/mL | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Zero to 24 h Postdose (AUC0-24h) of RO7126209 | 27.1 ± 23.2 | 124 ± 13.3 | 325 ± 27.1 | 1170 ± 13.3 | 2340 ± 16.5 |
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
| hr.µg/mL | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Zero to 168h Postdose (AUC0-168h) of RO7126209 | 78.0 ± 22.5 | 350 ± 14.2 | 807 ± 28.5 | 2940 ± 11.6 | 6190 ± 13.1 |
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
| hr.µg/mL | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Zero to the Last Measurable Concentration (AUC0-last) of RO7126209 | 86.9 ± 21.9 | 402 ± 14.4 | 933 ± 30.7 | 3380 ± 11.5 | 7070 ± 10.9 |
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
| hr.µg/mL | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) | 89.1 ± 21.7 | 417 ± 13.7 | 947 ± 29.3 | 3380 ± 11.5 | 7080 ± 10.9 |
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
| (1/h) | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|
| Terminal Rate Constant (Lambda z) of RO7126209 | 0.0103 ± 19.7 | 0.00625 ± 57.0 | 0.00690 ± 59.0 | 0.00409 ± 19.5 | 0.00436 ± 21.8 |
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
| hr | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|
| Apparent Terminal Half-Life (T1/2) of RO7126209 | 67.1 ± 19.7 | 111 ± 57.0 | 100 ± 59.0 | 170 ± 19.5 | 159 ± 21.8 |
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
| mL/hr/kg | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|
| Total Body Clearance Calculated as Dose/AUC (CL) of RO7126209 | 1.14 ± 21.3 | 0.965 ± 13.8 | 1.28 ± 29.4 | 1.07 ± 10.9 | 1.03 ± 11.1 |
Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.
| mL/kg | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|
| Volume of Distribution at Steady-State (Vss) of RO7126209 | 88.6 ± 25.1 | 90.3 ± 26.3 | 108 ± 35.5 | 88.7 ± 22.6 | 85.3 ± 22.8 |
RO7126209 CSF concentrations were measured by a specific and validated method. Geometric Mean and Coefficient of Variation data are presented below.
| µg/mL | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|
| Day 3 | 0.00414 ± 33.0 | 0.0202 ± 26.5 | 0.047 ± 29.4 | 0.105 ± 40.3 | 0.284 ± 35.9 |
| Day 5 | 0.00228 ± 18.7 | 0.0126 ± 26.1 | 0.0274 ± 22.9 | 0.0755 ± 7.4 | 0.151 ± 9.8 |
The numbers and proportions of Anti-Drug Antibody (ADA) positive participants and ADA negative participants at baseline (baseline prevalence) and after study drug administration (post-baseline incidence during both the treatment and follow-up periods) were summarized per dose group during both the treatment and follow-up period.
| Percentage of Participants | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|
| Percentage of Participants With Anti-RO7126209 Antibodies (ADAs) | 50.0 | 25.0 | 66.7 | 83.3 | 83.3 |
Collected over Up to approximately 9 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| RO7126209 (0.1 mg/kg) | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| RO7126209 (0.4 mg/kg) | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| RO7126209 (1.2 mg/kg) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| RO7126209 (3.6 mg/kg) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| RO7126209 (7.2 mg/kg) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | Placebo | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) |
|---|---|---|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 1/10 | 0/4 | 0/4 | 0/6 | 5/6 | 6/6 |
| HeadacheNervous system disorders | 5/10 | 0/4 | 1/4 | 5/6 | 1/6 | 3/6 |
| Back painMusculoskeletal and connective tissue disorders | 0/10 | 3/4 | 1/4 | 3/6 | 1/6 | 0/6 |
| NauseaGastrointestinal disorders | 3/10 | 0/4 | 0/4 | 3/6 | 2/6 | 0/6 |
| VomitingGastrointestinal disorders | 2/10 | 0/4 | 0/4 | 1/6 | 1/6 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 2/10 | 0/4 | 0/4 | 0/6 | 1/6 | 0/6 |
| ChillsGeneral disorders | 0/10 | 0/4 | 0/4 | 0/6 | 1/6 | 0/6 |
| Injection site extravasationGeneral disorders | 0/10 | 0/4 | 0/4 | 0/6 | 0/6 | 1/6 |
| ParaesthesiaNervous system disorders | 1/10 | 0/4 | 0/4 | 1/6 | 1/6 | 0/6 |
| PhlebitisVascular disorders | 0/10 | 0/4 | 0/4 | 0/6 | 0/6 | 1/6 |
| Age, Continuous(years) | Placebo | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 29.2 ± 6.6 | 30.8 ± 5.9 | 23.5 ± 4.5 | 24.2 ± 3.8 | 33.0 ± 5.9 | 33.3 ± 2.6 | 29.2 ± 6.1 |
| Sex: Female, Male(Participants) | Placebo | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 10 | 4 | 4 | 6 | 6 | 6 | 36 |
| Race/Ethnicity, Customized(Participants) | Placebo | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
| Not Hispanic or Latino | 10 | 4 | 4 | 6 | 5 | 4 | 33 |
| Race/Ethnicity, Customized(Participants) | Placebo | RO7126209 (0.1 mg/kg) | RO7126209 (0.4 mg/kg) | RO7126209 (1.2 mg/kg) | RO7126209 (3.6 mg/kg) | RO7126209 (7.2 mg/kg) | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 2 | 0 | 0 | 0 | 1 | 0 | 3 |
| Black or African American | 3 | 1 | 3 | 3 | 2 | 1 | 13 |
| White | 5 | 2 | 1 | 1 | 3 | 4 | 16 |
| Multiple | 0 | 1 | 0 | 1 | 0 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Aug 2019 to primary completion in Jul 2020, 11 months.
Results were first posted in Aug 2021, 1 year after primary completion.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 11 months is close to that.
Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trontinemab